Browse

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives

DC Field Value Language
dc.contributor.authorTaieb, Julien-
dc.contributor.authorMoehler, Markus-
dc.contributor.authorBoku, Narikazu-
dc.contributor.authorAjani, Jaffer A.-
dc.contributor.authorRuiz, Eduardo Yanez-
dc.contributor.authorRyu, Min-Hee-
dc.contributor.authorGuenther, Silke-
dc.contributor.authorChand, Vikram-
dc.contributor.authorBang, Yung-Jue-
dc.date.accessioned2021-01-31T11:07:06Z-
dc.date.available2021-01-31T11:07:06Z-
dc.date.issued2018-05-
dc.identifier.citationCancer Treatment Reviews, Vol.66, pp.104-113-
dc.identifier.issn0305-7372-
dc.identifier.other77845-
dc.identifier.urihttps://hdl.handle.net/10371/173035-
dc.description.abstractBackground: Standard treatment options for patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) are associated with limited efficacy and some toxicity. Recently, immunotherapy with antibodies that inhibit the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) interaction has emerged as a new treatment option. This manuscript reviews early-phase and late-phase trials of immunotherapy in advanced GC/GEJC. Methods: Searches for studies of immunotherapy in GC/GEJC were performed using PubMed, ClinicalTrials.gov, and abstract databases for select annual congresses. Findings were interpreted based on expert opinion. Results: Monotherapy with anti-PD-1/PD-L1 antibodies, including pembrolizumab, nivolumab, avelumab, durvalumab, and atezolizumab, has shown interesting objective response rates (ORRs; 7-26%) across varying GC/GEJC populations, with ORRs potentially higher in PD-L1 + vs PD-L1 - tumors. Safety profiles compare favorably with chemotherapy, with grade >= 3 treatment-related adverse events occurring in 5-17%. Based on a large phase 2 study, pembrolizumab was approved in the United States for third-line treatment of patients with PD-L1 + GC/GEJC. In a phase 3 trial, third-line or later nivolumab increased overall survival vs placebo in an Asian population, leading to regulatory approval in Japan, although other completed phase 3 trials did not show superiority for pembrolizumab or avelumab monotherapy vs chemotherapy. Other trials in advanced GC/GEJC are assessing various anti-PD-1/PD-L1-based strategies, including administration in first-line and later-line settings and as combination (with chemotherapy or agents targeting other immune checkpoint proteins, eg, CTLA-4, LAG-3, and IDO) or switch-maintenance regimens. Conclusions: Anti-PD-1/PD-L1 antibodies have shown encouraging clinical activity in advanced GC/GEJC. Results from ongoing phase 3 trials are needed to further evaluate the potential roles of these agents within the continuum of care.-
dc.subjectImmunotherapy-
dc.subjectImmune checkpoint inhibitors-
dc.subjectPD-1/PD-L1-
dc.subjectGastric-
dc.subjectGastroesophageal junction-
dc.titleEvolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1016/j.ctrv.2018.04.004-
dc.citation.journaltitleCancer Treatment Reviews-
dc.identifier.scopusid2-s2.0-85046642052-
dc.citation.endpage113-
dc.citation.startpage104-
dc.citation.volume66-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0305737218300380?via%3Dihub-
dc.identifier.rimsid77845-
dc.identifier.sci000435054400011-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse